Hepatitis A |
|
Inclusion criteria |
Florida residents meeting the surveillance case definition for hepatitis A† with symptom onset during November 1, 2021–November 30, 2022 |
Confirmed case |
A hepatitis A case with laboratory evidence of infection with HAV genotype IA, A17 cluster 21, or epidemiologically linked to a case with HAV A17 cluster 21 infection |
Probable case |
A hepatitis A case who identified as transgender or MSM or had sexual contact with MSM, irrespective of other risk factors for hepatitis A |
Suspected case |
A male hepatitis A case with unknown sexual history, and absence of other risk factors for hepatitis A (e.g., foreign travel, drug use, homelessness, incarceration) |
Epidemiologically linked |
Household or sexual contact during the 15–50 d before symptom onset |
Exclusions
|
Cases with sequencing results indicating infection with HAV other than genotype IA, A17 cluster 21
|
Invasive meningococcal disease |
|
Inclusion criteria |
Florida residents meeting the surveillance case definition for invasive meningococcal disease† with symptom onset during November 1, 2021–November 30, 2022 |
Confirmed case |
An invasive meningococcal disease case who identifies as MSM or had sexual contact with MSM and evidence of serogroup C infection; or laboratory evidence of infection with ST11 CC11 serogroup C, with <100 SNPs difference to the outbreak strain, irrespective of sexual history |
Probable case |
An invasive meningococcal disease case who identifies as MSM or had sexual contact with MSM and for whom no additional serogroup, ST, or CC typing is available; or who had evidence of serogroup C infection regardless of sexual history |
Exclusions
|
Cases with sequencing results indicating infection with Neisseria meningitides other than ST11 CC11 serogroup C or with >100 SNP differences to the outbreak strain
|
Mpox |
|
Inclusion criteria |
Florida residents meeting the surveillance case definition for confirmed or probable mpox‡ with symptom onset during May 1–November 30, 2022 |